The Insulin-like Growth Factor (IGF) signaling system plays a central role in cellular growth, differentiation and proliferation. IGFBP3 is the most abundant IGF binding protein in human serum and has been shown to be a growth inhibitory, apoptosis-inducing molecule, capable of acting via IGF-dependent and IGF-independent mechanisms. It appears to function both by cell cycle blockade and the induction of apoptosis. IGFBP3 can be transported to the nucleus by an importin beta mediated mechanism, where it has been shown to interact with the retinoid X receptor alpha and possibly other nuclear elements. IGFBP3 antiproliferative signalling appears to require an active transforming growth factor beta (TGF-beta) signalling pathway, and IGFBP3 stimulates phosphorylation of the TGF-beta signalling intermediates Smad2 and Smad3. IGFBP3 has IGF-independent roles in inhibiting cell proliferation in cancer cell lines. Nuclear transcription factor, retinoid X receptor (RXR)-alpha, and IGFBP3 functionally interact to reduce prostate tumor growth and prostate-specific antigen in vivo. Several clinical studies have proposed that individuals with IGFBP3 levels in the upper range of normal may have a decreased risk for certain common cancers. This includes evidence of a protective effect against breast cancer, prostate cancer, colorectal cancer, and lung cancer. Moreover, IGFBP3 inhibits insulin-stimulated glucose uptake into adipocytes independent of IGF.
Product Name:
Human IGFBP3/IBP3 Recombinant Protein (RPES3296)
Product Code:
RPES3296
Size:
5µg
Species:
Human
Expressed Host:
HEK293 Cells
Synonyms:
BP-53,IBP3,IGFBP3
Accession:
NP_000589.2
Sequence:
Gly28-Lys 291
Fusion tag:
N-His
Activity:
1. Measured by its binding ability in a functional ELISA. Immobilized human IGF2 at 10 µg/mL (100 ?l/well) can bind biotinylated Human His-IGFBP3, The EC50 of biotinylated Human His-IGFBP3 is 18 ng/mL.2. Measured by its binding ability in a functional ELISA. Immobilized human IGF1 at 10 µg/mL (100 ?l/well) can bind biotinylated Human His-IGFBP3, The EC50 of biotinylated Human His-IGFBP3 is 24 ng/mL.3. Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human breast adenocarcinoma cells (Karey, K.P. et al. (1988) Cancer Research 48:4083.). The ED50 for this effect is typically 0.02-0.2 µg/mL in the presence of 14 ng/mL human IGFII.
Endotoxin:
<1.0 EU per µg as determined by the LAL method.
Protein Construction:
A DNA sequence encoding the mature form of human IGFBP3 (NP_000589.2) (Gly28-Lys 291) was fused with a polyhistidine tag at the N-terminus.
Purity:
> 85 % as determined by reducing SDS-PAGE.
Mol Mass:
31 kDa
AP Mol Mass:
40-45 kDa
Formulation:
Lyophilized from sterile PBS, pH 7.4
Shipping:
This product is provided as lyophilized powder which is shipped with ice packs.
Stability and Storage:
Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
